New combination therapy for hepatitis C

May 5, 2014, Medical University of Vienna
New combination therapy for hepatitis C
New combination therapy for hepatitis C

A new combination therapy allows chronic hepatitis C to be treated in a manner that is less aggressive yet equally efficient. This is the result of a current study, led by primary author Peter Ferenci from the University Department of Internal Medicine III at the MedUni Vienna, which has been published in the highly respected New England Journal of Medicine. "This is a revolutionary breakthrough in the treatment of this disease and represents a huge improvement in the quality of life of those affected," says the Vienna hepatologist.

Ferenci and a global group of scientists were able to demonstrate using 419 test subjects with C that the combined use of the ABT-450r, the NS5A inhibitor Ombitasvir and the non-nucleoside polymerase inhibitor Dasubavir yields significantly higher cure outcomes than the previous therapy which involves Ribavarin and the hormone interferon (mostly in combination with a protease inhibitor). These therapies also had considerable side effects. The in these current "PEARL" studies were all in the early stages of the disease, i.e. before liver cirrhosis had developed.

Twelve weeks of treatment - almost a 100 per cent cure rate

Says Ferenci: "After just twelve weeks, we had achieved an almost one hundred per cent cure rate with this new, side-effect-free therapy." The therapy involves three tablets – two in the morning and one in the evening. Until now, patients with hepatitis C had to take Ribavirin and the hormone interferon for up to 18 months, and the side effects were considerable. "Often, additional treatment was and is necessary," explains Ferenci. With the new combination therapy, which is also free of interferon, this additional therapy is not required.

Around 170 million people worldwide suffer from chronic hepatitis C, and in Austria these numbers are between 40,000 and 80,000. In cases of new infection, prompt and targeted therapy is vital, as it can prevent the disease developing into a that can lead to . In the Clinical Gastroenterology and Hepatology Unit at the University Department of Internal Medicine III, several hundred patients with chronic hepatitis C are currently seen and treated each year.

Due to the low number of symptoms, infected individuals often mistake the disease for a 'flu-like infection. The condition is in many cases diagnosed by a chance finding.

Hepatitis C is an inflammation of the liver caused by an infection with the hepatitis C virus. The virus is transmitted mostly via direct contact with contaminated blood or blood products. At-risk groups are primarily drug abusers who share needles with others. Transmission through everyday activities is virtually impossible.

Explore further: Hepatitis C: New points system helps with disease prognosis

More information: ABT-450/Ritonavir/Ombitasvir and Dasabuvir With or Without Ribavirin for HCV Genotype 1. P. Ferenci, D. Bernstein, J. Lalezari, D. Cohen, Y. Luo, C. Cooper, E.Tam, Rui T. Marinho, N. Tsai, A. Nyberg, T. D. Box, Z. Younes, P. Enayati, S. Green, Y. Baruch, B. Bhandari, F. Caruntu, T. Sepe, V. Chulanov, E. Janczewska, G. Rizzardini, J. Gervain, R. Planas, C. Moreno, T. Hassanein, W. Xie, M. King, T. Podsadecki and K. Reddy. New Engl. J. Med 2014 (in press). The complete article is available online: www.nejm.org/doi/full/10.1056/NEJMoa1402338

Related Stories

Hepatitis C: New points system helps with disease prognosis

July 29, 2013
Between 40,000 and 80,000 Austrians suffer from hepatitis C. With new infections the prompt and appropriate treatment is of great importance as this can prevent it developing into a chronic illness which in turn can progress ...

New combination drug therapy proves very effective in Hepatitis C treatments

April 12, 2014
Treatment options for the 170 million people worldwide with chronic Hepatitis C Virus (HCV) are evolving rapidly, although the available regimens often come with significant side effects. Two multi-center clinical trials ...

Impressive SVR12 data for once-daily combination to treat HCV genotype 1 patients

April 12, 2014
Results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational once-daily fixed-dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400mg and the NS5A inhibitor ...

Doctor details two new hepatitis C drugs

December 20, 2013
In the last three weeks, the Food and Drug Administration has approved two new drugs that are expected to dramatically improve treatment of chronic hepatitis C, a liver-damaging viral infection that afflicts more than 3.2 ...

FDA approves new treatment for hepatitis C infection

November 25, 2013
(HealthDay)—The U.S. Food and Drug Administration has approved a new drug for chronic hepatitis C infection that some experts hope will cut down on side effects from current therapies.

Hepatitis C remains major problem for HIV patients despite antiretroviral therapy

March 17, 2014
A new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania has found that the risk of hepatitis C-associated serious liver disease persists in HIV patients otherwise benefitting from ...

Recommended for you

RNA processing and antiviral immunity

December 14, 2018
The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Researchers discover new interactions between Ebola virus and human proteins

December 13, 2018
Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ...

Faecal transplants, 'robotic guts' and the fight against deadly gut bugs

December 13, 2018
A simple compound found in our gut could help to stop dangerous bacteria behind severe, and sometimes fatal, hospital infections.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.